PhRMA-backed alliance says it wants to 'modernize' the 340B program. Critics say the changes will only limit access
The Alliance to Save America’s 340B Program (ASAP 340B) is made up of a coalition of biopharma stakeholders who last week released a set of changes it thinks should be made to the discount program, sparking a rebuttal from opposing organizations who say the changes will only limit access to necessary meds.
Established in 1992, 340B is a federal health program that requires pharma companies to offer discounts on their drugs to hospitals that treat low-income patients. But drugmakers over the last year have claimed the program is being abused by hospitals and have set their own restrictions.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters